Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
Green SM changes its brand from Xanh SM to Green SM. The Green Smart Mobility and Intelligent Transport Joint Stock Company (GSM) announced the brand change from Xanh SM to Green SM. The change aims to unify brand identity across the entire system and marks the company's three-year operation. In…
On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares fall sharply after the company announced it had stopped its Phase 3 Hunger Elimination of Reduction Objective (“HERO”) trial evaluating ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome (“PWS”). The stock dropped $7.02, or 56%, following the announcement.
Aardvark said it stopped the HERO trial due to a serious safety risk, specifically “reversible cardiac observations.” The company also stated it no longer anticipates announcing topline data from the HERO trial during the third quarter of 2026.
The development and the market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws. The firm encouraged Aardvark investors who suffered substantial losses to submit their losses and urged persons with knowledge who may be able to assist the investigation to contact its attorneys.
According to Hagens Berman, the investigation centers on the propriety of Aardvark’s disclosures regarding ARD-101 safety and efficacy data, as well as disclosures relating to communications with the FDA.
In prior communications, Aardvark emphasized that ARD-101 was a “first-in-class” drug and described its HERO trial enrollment and dosing approach, including starting with patients 13 years and older, moving to dosing patients 10 years and older, and intending to dose patients as young as 4 years old.
The company also assured investors that ARD-101 had “a very tolerable safety profile.”
After the March 2 announcement, the stock fell by more than half. With the emergence of cardiac safety signals, the article states that several analysts reportedly reduced or suspended their price targets.
“We’re focused on whether Aardvark may have misled investors about ARD-101’s development, its safety and/or efficacy, and the company’s communications with the FDA,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
The article also references the SEC Whistleblower program, stating that whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
Contact listed in the article: Reed Kathrein, 844-916-0895.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
